April 29, 2024 07:17 AM EDT
R&D

As­traZeneca, Dai­ichi Sankyo’s En­her­tu claims an­oth­er Phase 3 vic­to­ry in HER2-low breast can­cer

Ayisha Sharma

News Reporter

En­her­tu notched an­oth­er win for As­traZeneca and Dai­ichi Sankyo that could see up­take moved slight­ly ear­li­er in a spe­cif­ic sub­set of breast can­cer pa­tients. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times